Meeting
2022 ASCO Annual Meeting
Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
Authors
Christie Zettler
Columbia University Medical Center, New York, NY
Christie Zettler , Dilanka De Silva , Victoria Susana Blinder , Mark E. Robson , Elena B. Elkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6593)
DOI
10.1200/JCO.2022.40.16_suppl.6593
Abstract #
6593
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
First Author: Christopher Lemmon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma.
First Author: J. Alberto Maldonado
Poster
2022 ASCO Genitourinary Cancers Symposium
Cost effectiveness of adjuvant pembrolizumab after nephrectomy for RCC: Insights for patient selection from a Markov model.
First Author: Vidit Sharma
Poster
2020 ASCO Quality Care Symposium
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
First Author: Edward C. Li